

# Progressive Multifocal Leukoencephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/P579580B6FB8EN.html>

Date: October 2022

Pages: 39

Price: US\$ 2,000.00 (Single User License)

ID: P579580B6FB8EN

## Abstracts

Progressive Multifocal Leukoencephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Multifocal Leukoencephalopathy - Drugs In Development, 2022, provides an overview of the Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline landscape.

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain caused by lytic infection of oligodendrocytes by the JC polyomavirus. Symptoms include clumsiness, progressive weakness, and visual, speech, and sometimes personality changes. Risk factors include the presence of pathogenic JCV and an altered or weakened immune system, genetic or environmental factors.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Progressive Multifocal Leukoencephalopathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press

releases.

The Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase I, Phase 0, Preclinical and Discovery stages are 1, 1, 4 and 3 respectively.

Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Multifocal Leukoencephalopathy (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Progressive Multifocal Leukoencephalopathy - Overview

Progressive Multifocal Leukoencephalopathy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Progressive Multifocal Leukoencephalopathy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Progressive Multifocal Leukoencephalopathy - Companies Involved in Therapeutics Development

Biological E Ltd

Cellevolve Bio

Evrys Bio

Excision BioTherapeutics Inc

Genexine Inc

Inhibikase Therapeutics Inc

Neurimmune Holding AG

Pomona Ricerca SRL

Vir Biotechnology Inc

Progressive Multifocal Leukoencephalopathy - Drug Profiles

CEVST-01JC - Drug Profile

Product Description

Mechanism Of Action

EBT-103 - Drug Profile

Product Description

Mechanism Of Action

efineptakin alfa - Drug Profile

Product Description

Mechanism Of Action

IkT-01427 - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody for John Cunningham Infections and Progressive Multifocal

Leukoencephalopathy - Drug Profile

Product Description

Mechanism Of Action

NI-307 - Drug Profile

Product Description

Mechanism Of Action

PNJC-1 - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile

Product Description

Mechanism Of Action

Vaccine for Progressive Multifocal Leukoencephalopathy - Drug Profile

Product Description

Mechanism Of Action

Progressive Multifocal Leukoencephalopathy - Dormant Projects

Progressive Multifocal Leukoencephalopathy - Product Development Milestones

Featured News & Press Releases

Sep 20, 2022: Cellevolve Bio submits Investigational New Drug (IND) application for global phase 2, placebo-controlled study of CE-VST01-JC for the treatment of Progressive Multifocal Leukoencephalopathy (PML)

Dec 01, 2021: Cellevolve announces global partnership with QIMR Berghofer Medical Research Institute to advance novel off-the shelf T-cell therapy in the first randomized cell therapy trial for progressive multifocal leukoencephalopathy (PML)

May 24, 2021: NeoImmuneTech announces first patient dosed in the pilot study of NT-I7 (efineptakin alfa) in progressive multifocal leukoencephalopathy

Feb 23, 2021: NeoImmuneTech receives U.S. FDA IND clearance for pilot study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy

Jun 15, 2020: NeoImmuneTech receives FDA orphan drug designation for NT-I7 (efineptakin alfa) for the treatment of progressive multifocal leukoencephalopathy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Progressive Multifocal Leukoencephalopathy, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Progressive Multifocal Leukoencephalopathy - Pipeline by Biological E Ltd, 2022

Progressive Multifocal Leukoencephalopathy - Pipeline by Cellevolve Bio, 2022

Progressive Multifocal Leukoencephalopathy - Pipeline by Evrys Bio, 2022

Progressive Multifocal Leukoencephalopathy - Pipeline by Excision BioTherapeutics Inc, 2022

Progressive Multifocal Leukoencephalopathy - Pipeline by Genexine Inc, 2022

Progressive Multifocal Leukoencephalopathy - Pipeline by Inhibikase Therapeutics Inc, 2022

Progressive Multifocal Leukoencephalopathy - Pipeline by Neurimmune Holding AG, 2022

Progressive Multifocal Leukoencephalopathy - Pipeline by Pomona Ricerca SRL, 2022

Progressive Multifocal Leukoencephalopathy - Pipeline by Vir Biotechnology Inc, 2022

Progressive Multifocal Leukoencephalopathy - Dormant Projects, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Progressive Multifocal Leukoencephalopathy, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022



## I would like to order

Product name: Progressive Multifocal Leukoencephalopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/P579580B6FB8EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P579580B6FB8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

